Is there an official taper schedule for Ozempic, Wegovy, Mounjaro, or Zepbound?

No. Neither Novo Nordisk (Ozempic, Wegovy) nor Eli Lilly (Mounjaro, Zepbound) publish a formal tapering protocol in their FDA prescribing information. Any specific step-down schedule you've seen online is clinical convention, not manufacturer or regulatory guidance.

Does tapering actually reduce weight regain compared to stopping abruptly?

There's no published trial comparing the two approaches for weight regain outcomes. The World Health Organization's December 2025 GLP-1 obesity guideline explicitly notes that limited data are currently available on discontinuation decisions and their health impact. Tapering is convention, not evidence-based practice.

Why do prescribers still recommend tapering if there's no evidence?

The rationale is physiological, not outcomes-based: a slower step-down may soften the appetite rebound, reduce the psychological shock of full hunger returning at once, and — for people on higher doses — provide a chance to notice regain drift early enough to intervene. These are reasonable arguments, but they haven't been formally tested.

Can I just stop cold-turkey?

Many people do — often because insurance dropped coverage, cost changed, side effects became intolerable, or a shortage forced the issue. There's no known safety issue with stopping abruptly; the question is whether a gradual step-down would have made the appetite transition easier, not whether abrupt cessation is dangerous.

What does a typical GLP-1 taper look like?

A common approach is stepping down the same doses that were stepped up during initiation, holding each dose for 4 or more weeks — for example, moving from 2.4 mg semaglutide back through 1.7, 1.0, 0.5, and 0.25 mg over 8–16 weeks. This mirrors the manufacturer titration schedule in reverse and is what most tapering protocols in clinic settings look like, but it is not an official recommendation.

Tapering Off GLP-1: Cold Turkey vs Step-Down

Q: Does tapering matter more for tirzepatide than semaglutide?

Tirzepatide has a shorter half-life (~5 days vs ~7), so the appetite rebound tends to arrive sooner after cessation. That's an argument some prescribers make for slower tapering — but again, without evidence that it changes outcomes.

Written by the GLP-1 Coach editorial team. Last updated August 13, 2026.

"Should I taper off my GLP-1, or stop cold-turkey?" is one of the most commonly searched decisions people make near the end of their treatment window. It's also one where the confident-sounding schedules online are downstream of essentially no clinical evidence.

Here is what actually exists, what's convention, and how to think about the decision with your prescriber.

What does "tapering" even mean for a weekly injectable?

Tapering for GLP-1s doesn't look like tapering for something like an SSRI or a steroid. Because the drug is dosed once weekly, tapering means one of two things:

Stepping down the dose in the reverse order of titration — for example, moving from a maintenance dose of semaglutide 2.4 mg (Wegovy) back through 1.7 mg, 1.0 mg, 0.5 mg, and 0.25 mg over roughly 8 to 16 weeks, with each dose held for 4 or more weeks.
Stretching the interval between doses — for example, moving from weekly to every-other-week, then every-third-week, before stopping entirely. This is less common in formal clinic protocols and is more often seen in real-world compounded semaglutide use.

The first approach mirrors the manufacturer titration schedule in reverse and is the most commonly seen "taper" in clinical practice. The second approach lacks any real published support and is not typically recommended by endocrinology or obesity medicine sources.

What do the FDA labels actually say about stopping?

This is the part that surprises most people who go looking for a definitive answer:

Nothing. Or more precisely: neither the Wegovy nor the Ozempic prescribing information from Novo Nordisk includes a formal tapering protocol. Neither does Eli Lilly's Mounjaro or Zepbound prescribing information. Both companies describe how to escalate doses, but treat discontinuation as an event, not a protocol.

The most authoritative recent statement on the question is from the World Health Organization's December 2025 guideline on GLP-1 medicines in obesity, which states plainly that "limited data are currently available to inform practice around decisions about, or the health impact of, discontinuation." This is unusually blunt language from a body that normally hedges more carefully.

So when you see "the standard taper schedule is X weeks," what you are seeing is one clinician's version of a reasonable-sounding stepdown, not something derived from a trial that showed better outcomes than stopping directly.

Why do prescribers still taper anyway?

Because "no evidence for X is better than Y" isn't the same as "X is pointless." There are physiologically reasonable arguments for tapering:

A gradual dose reduction may soften the appetite rebound. Rather than the drug going from steady-state to fully cleared over ~5 weeks (semaglutide) or ~3–4 weeks (tirzepatide), a taper can extend the transition by months, giving appetite regulation more time to recalibrate incrementally.
A slower step-down reveals regain drift earlier. At a lower maintenance dose, you're still receiving some appetite suppression, so any weight movement is more likely to be habit-driven than drug-clearance-driven. That's arguably an easier signal to interpret than "everything is different at once."
The psychological transition is less abrupt. For many people, the biggest challenge of stopping isn't the hunger itself but the mental shift of losing the appetite support they'd relied on. A taper spreads that mental adjustment across weeks rather than compressing it into a few days.
For higher doses (Wegovy 2.4 mg, Zepbound 15 mg), the drop to zero is bigger. The argument for tapering is often strongest at the top of the dose range, where the pharmacological effect being removed is largest.

None of these are outcome studies. All of them are reasonable clinical inferences. That distinction matters.

What does a step-down schedule actually look like in practice?

If you and your prescriber decide on a taper, the most common shape in clinical practice mirrors the manufacturer titration schedule in reverse. For semaglutide (Wegovy):

Weeks	Dose
1–4	1.7 mg weekly (down from 2.4 mg)
5–8	1.0 mg weekly
9–12	0.5 mg weekly
13–16	0.25 mg weekly
17+	Discontinued

For tirzepatide (Zepbound), a comparable pattern would step down through the same doses used during titration — for example 15 → 12.5 → 10 → 7.5 → 5 → 2.5 mg, with 4 weeks at each step.

Two important caveats:

Neither manufacturer publishes this schedule. It is a clinical convention, and the specific timing varies widely across prescribers.
Not every dose step in the titration schedule is one many people have actually used. Someone who titrated quickly from 1 mg to 2.4 mg Wegovy without stopping at 1.7 mg long-term may have no personal experience at that intermediate dose — the taper is not necessarily a "familiar" reverse trip.

When does cold-turkey make more sense?

For a significant number of people, tapering isn't the actual choice being made — it's the choice they'd have made if life had cooperated.

Common reasons for abrupt discontinuation:

Insurance dropped coverage. Payer discontinuations have become one of the most common triggers for stopping GLP-1s, particularly for obesity indications. A step-down schedule at compounding pharmacy prices is often not financially realistic.
Cost changed. Even with continued coverage, out-of-pocket costs can shift enough to force the decision.
A shortage forced the issue. Semaglutide and tirzepatide have both experienced periods of supply constraint that made maintaining a specific taper schedule impossible.
Side effects became intolerable. Some people stop because the side effects at their current dose aren't sustainable and a step-down doesn't happen fast enough to help.
A pregnancy is planned. Both manufacturers recommend stopping at least 2 months before a planned pregnancy — a specific washout requirement that is not a taper but an outright stop.
The person reached their weight goal and decided the transition was worth it.

There is no known safety issue with abrupt cessation of a GLP-1. You will not experience physical withdrawal in any meaningful clinical sense. The trade-off is only about the smoothness of the appetite transition — not about whether stopping is safe.

What does stopping abruptly look like compared to tapering?

Neither approach has been directly compared in a randomized trial, but here's what the pharmacokinetics predict for each:

	Cold-turkey stop	Taper (typical 8–16 week step-down)
Full drug clearance	~5 weeks (sema) / ~3–4 weeks (tirz)	Extended over the full taper duration
Appetite rebound arrival	Distinct in weeks 1–2	Gradual and less clearly bounded
Ability to notice early regain drift	Harder — everything changes at once	Easier — smaller shifts per step
Cost during transition	None after last dose	Continued for the full taper
Availability required	None after last dose	Continued for the full taper
Impact on longer-term regain (STEP-1 / SURMOUNT-4 pattern)	Unknown — no trial comparison	Unknown — no trial comparison

The final row is the honest answer to "which is better." Neither the STEP-1 extension nor SURMOUNT-4 tested tapering vs abrupt cessation — both used abrupt discontinuation as the study design, and both showed substantial regain patterns. Whether tapering would have changed those numbers is genuinely not known.

Does tapering matter more for tirzepatide than semaglutide?

There is a defensible physiological argument that it does. Because tirzepatide clears in ~3–4 weeks vs semaglutide's ~5, the appetite rebound after cessation arrives sooner and moves faster. A step-down could theoretically dampen that steepness more than it would for semaglutide.

The SURMOUNT-4 trial itself showed a roughly 20-percentage-point weight swing between people who continued tirzepatide and people switched to placebo over the year following the lead-in, a much larger gap than the equivalent semaglutide numbers — for the full breakdown, see what actually happens when you stop Mounjaro or Zepbound. If that gap is at all attributable to the speed of the transition rather than the removal of the drug itself, tapering could matter more.

But this is inference, not measurement. It is a plausible reason to prefer tapering for tirzepatide specifically — not evidence that tapering changes outcomes.

The bottom line

Bottom line: There is no FDA-labeled or WHO-recommended tapering protocol for any GLP-1. Tapering is clinical convention that has never been formally shown to change regain outcomes vs abrupt cessation. It's a physiologically reasonable choice — particularly at higher doses and for tirzepatide — but it's a preference decision made with your prescriber, not a proven better option. Cold-turkey stops are safe; they are also often not a choice but a circumstance.

Related tool: once you've decided on your last-dose date, our free post-therapy timeline calculator shows what to expect week by week.

Final Thoughts

The most useful reframe for this decision is that tapering vs cold-turkey is not really a question about safety or evidence — it's a question about which transition shape you'd prefer to manage, and whether continuing to pay for and take the drug during the step-down is realistic for your situation.

If cost, coverage, and adherence are all working in your favor and you'd like a slower, more decoded transition, tapering under a prescriber's schedule is a reasonable choice. If any of those aren't in your favor, cold-turkey is neither dangerous nor obviously worse — the STEP-1 and SURMOUNT-4 regain patterns describe what happens after abrupt cessation, and the outcomes were not catastrophic; roughly two-thirds regain over a year is a common trajectory (detailed in what actually happens when you stop Wegovy), but a meaningful subset of people held most of their loss. And because regained weight tends to come back as fat rather than muscle, the protein and resistance work matters regardless of which stopping method you use.

The single largest predictor of what happens after your last dose — regardless of taper vs abrupt — is the habit stack you built during treatment. Protein consistency, meal structure, and resistance activity are what determine the shape of the regain curve, not the shape of the taper. For the broader post-medication transition, life after Ozempic: how to maintain weight loss after stopping covers the first 8–12 weeks in detail. And if you're weighing a planned stop vs planning to restart later, restarting Ozempic after a break explains the re-titration timeline and what changes on a second course.

The taper decision is worth having with your prescriber. It's not worth agonizing over alone.

Related:

This article is educational and not a substitute for medical advice. Any decision to taper, stop, or continue a GLP-1 medication should be made with the prescriber managing your care.

Sources: WHO Global Guideline on GLP-1 Medicines for Obesity, December 2025; Wilding et al., STEP 1 extension, Diabetes, Obesity and Metabolism 2022; Aronne et al., SURMOUNT-4, JAMA 2023; Wegovy prescribing information, FDA; Zepbound prescribing information, Eli Lilly.